Quick Answer
Sarepta Therapeutics, Inc. reported Long-Term Debt of $1.48 million for fiscal year 2014.
Sarepta Therapeutics, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2014 | $1.48M | -6.3% |
| 2013 | $1.58M | -5.5% |
| 2012 | $1.67M | -5.1% |
| 2011 | $1.76M | -4.6% |
| 2010 | $1.84M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| March 31, 2015 | $1.45M | -6.5% | -1.8% |
| December 31, 2014 | $1.48M | -6.3% | -1.7% |
| September 30, 2014 | $1.50M | -6.1% | -1.6% |
| June 30, 2014 | $1.52M | -6.0% | -1.7% |
| March 31, 2014 | $1.55M | -5.7% | -1.6% |
| December 31, 2013 | $1.58M | -5.5% | -1.4% |
| September 30, 2013 | $1.60M | -5.4% | -1.4% |
| June 30, 2013 | $1.62M | -5.3% | -1.4% |
- Sarepta Therapeutics, Inc. showed a decrease of -6.3% in Long-Term Debt compared to the prior fiscal year.
- Over the 2010–2014 period, Sarepta Therapeutics, Inc.’s long-term debt has declined by 19.9% (from $1.84 million to $1.48 million).
- The most recent figure is from Sarepta Therapeutics, Inc.’s fiscal year 2014 report (Form 10-K), filed with the SEC on February 26, 2015.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: